Asia-Pacific In-Vitro Fertilization (IVF) Market Introduction and Overview
According to SPER Market Research, the Asia-Pacific In-Vitro Fertilization (IVF) Market is estimated to reach USD 63.52 Billion by 2033 with a CAGR of 17.24%.
The report includes an in-depth analysis of the Asia-Pacific In-Vitro Fertilization (IVF) Market, including market size and trends, product mix, applications, and supplier analysis. An assisted reproductive technology (ART) process called in vitro fertilisation (IVF) involves fertilising egg cells with sperm outside of the woman's body and then implantation of the resulting embryo(s) into the uterus. This procedure helps with conception by addressing genetic or reproductive problems. It includes the collection of sperm and egg cells, followed by a manual combining process in a lab to create embryos. After that, the uterus receives these embryos to continue their development. IVF is frequently used to help individuals and couples, including LGBT people, single mothers, and those who are struggling with infertility.
- In March 2020: In order to educate infertile couples about medical advancements, Gurugram Hospital launched a Specialised Infertility Programme and Awareness Campaign. The programme involves sharing IVF success stories with the public, demonstrating how the availability of cutting-edge technology is assisting couples in embracing motherhood.
- In 2020: Vit Kit-NX is a vitrification medium solution that Fujifilm Irvine Scientific introduced with the goal of protecting embryos and achieving excellent survival rates. Thus, it is projected that the market will develop as a result of an increase in product approvals, product launches, and partnerships for IVF services.
Market Opportunities and Challenges
Rising acceptability of IVF procedures, rising IVF success rates, and rising public knowledge of IVF procedures are the main factors driving the growth of the worldwide Asia-Pacific IVF services market. With further technological advances, the success rate of in vitro fertilisation is increasing. Pre-implantation genetic diagnosis (PGD), intracytoplasmic sperm injection (ICSI), and in vitro maturation (IVM), among other cutting-edge IVF procedures, have contributed to higher pregnancy success rates. It is projected that IVF treatments in India will be driven by decreased costs, a looser fertility regulation, and an increased age restriction. Moreover, people choose to fly to Asia, where donor egg IVF is permitted, while donor egg IVF services are not offered in certain nations, such as Germany and Italy. As a result, patients choose less expensive fertility destinations, opening up opportunities for expansion for the Asia-Pacific IVF services industry.
However, the use of IVF services is restricted by side effects of the therapy, such as multiple pregnancies and birth problems. The number of embryos transferred determines the success percentage of IVF and can result in multiple pregnancies. Multiple pregnancies can lead to difficulties such as high blood pressure and delivery-related issues. Additionally, a kid may experience a number of health issues as a result of numerous pregnancies, including low birth weight and early delivery. Furthermore, ectopic pregnancy—a condition in which the embryo implants outside of the woman's womb and poses a threat to her life—is another possible risk of IVF treatment. These issues restrict the uptake of IVF operations, which impedes the expansion of the market.
Market Competitive Landscape
In vitro fertilisation (IVF) clinics, technology companies, and healthcare providers of all stripes compete in the Asia-Pacific IVF market by providing IVF services and solutions. The major key players in the Asia-Pacific In-Vitro Fertilization (IVF) Market are: Alcon, Bausch Health Companies Inc., Carl Zeiss AG, Cooper Companies, Johnson & Johnson, MaxiVision Eye Hospital, Rayner Surgical Group Limited, Schwind eye-tech-solutions GmbH & co.kg., STAAR Surgical Company, Ziemer Group AG, Others. A number of variables, including success rates, available technology, cost, and patient experience, influence competition.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Cycle Type, By End User
|
| Regions covered | Australia, China, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Vietnam, Rest of Asia-Pacific |
| Companies Covered | Alcon, Bausch Health Companies Inc., Carl Zeiss AG, Cooper Companies, Johnson & Johnson, MaxiVision Eye Hospital, Rayner Surgical Group Limited, Schwind eye-tech-solutions GmbH & co.kg., STAAR Surgical Company, Ziemer Group AG, Others
|
COVID-19 Impact on Asia-Pacific In-Vitro Fertilization (IVF) Market
The Asia-Pacific IVF services industry is expected to grow more slowly as a result of the COVID-19 pandemic. Numerous nations implemented lockdowns at the national level, which had a direct effect on fertility tourism as a result of aircraft delays, travel restrictions and quarantines, cancellation of all indoor and outdoor events, and emergency declarations. A great deal of clinics and hospitals underwent structural changes in order to accommodate more COVID-19 patients. Due to doctors' direct interaction with patients seeking IVF therapy, non-urgent patient visits to fertility clinics were discouraged, and elective fertility treatments were delayed. These elements therefore caused the cancellation of numerous planned IVF treatments and were predicted to impede the expansion of the Asia-Pacific IVF market throughout the pandemic.
Key Target Audience
- Fertility Clinics and Centers
- Pharmaceutical Companies
- Medical Device Manufacturers
- Hospitals and Clinics
- Research Institutions
- Others
Our in-depth analysis of the Asia-Pacific In-Vitro Fertilization (IVF) Market includes the following segments:
|
By Cycle Type:
|
Donor Egg IVF Cycle
Fresh Cycle (Non-Donor)
Thawed IVF Cycle (Non-Donor)
|
|
By End User:
|
Clinical Research Institutes
Fertility Clinics
Hospitals
Surgical Centers
|
|
By Region:
|
Australia
China
India
Indonesia
Japan
Malaysia
Myanmar
New Zealand
Philippines
Singapore
South Korea
Thailand
Vietnam
Rest of Asia-Pacific
|
Key Topics Covered in the Report
- Asia-Pacific In-Vitro Fertilization (IVF) Market Size (FY’2023-FY’2033)
- Overview of Asia-Pacific In-Vitro Fertilization (IVF) Market
- Segmentation of Asia-Pacific In-Vitro Fertilization (IVF) Market By Cycle Type (Donor Egg IVF Cycle, Fresh Cycle, Thawed IVF Cycle)
- Segmentation of Asia-Pacific In-Vitro Fertilization (IVF) Market By End User (Clinical Research Institutes, Fertility Clinics, Hospitals, Surgical Centers)
- Statistical Snap of Asia-Pacific In-Vitro Fertilization (IVF) Market
- Expansion Analysis of Asia-Pacific In-Vitro Fertilization (IVF) Market
- Problems and Obstacles in Asia-Pacific In-Vitro Fertilization (IVF) Market
- Competitive Landscape in the Asia-Pacific In-Vitro Fertilization (IVF) Market
- Impact of COVID-19 and Demonetization on Asia-Pacific In-Vitro Fertilization (IVF) Market
- Details on Current Investment in Asia-Pacific In-Vitro Fertilization (IVF) Market
- Competitive Analysis of Asia-Pacific In-Vitro Fertilization (IVF) Market
- Prominent Players in the Asia-Pacific In-Vitro Fertilization (IVF) Market
- SWOT Analysis of Asia-Pacific In-Vitro Fertilization (IVF) Market
- Asia-Pacific In-Vitro Fertilization (IVF) Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Asia-Pacific In-Vitro Fertilization (IVF) Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Asia-Pacific In-Vitro Fertilization (IVF) Market
7. Asia-Pacific In-Vitro Fertilization (IVF) Market, By Cycle Type (USD Million)
7.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Value Share and Forecast, By Cycle Type, 2023-2033
7.2. Donor Egg IVF Cycle
7.3. Fresh Cycle (Non-Donor)
7.4. Thawed IVF Cycle (Non-Donor)
8. Asia-Pacific In-Vitro Fertilization (IVF) Market, By End User (USD Million)
8.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Value Share and Forecast, By End User, 2023-2033
8.2. Clinical Research Institutes
8.3. Fertility Clinics
8.4. Hospitals
8.5. Surgical Centers
9. Asia-Pacific In-Vitro Fertilization (IVF) Market Forecast, 2019-2033 (USD Million)
9.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share
10. Asia-Pacific In-Vitro Fertilization (IVF) Market, By Cycle Type, 2019-2033 (USD Million)
10.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Cycle Type (2019-2026)
10.2. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Cycle Type (2027-2033)
11. Asia-Pacific In-Vitro Fertilization (IVF) Market, By End User, 2019-2033 (USD Million)
11.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By End User (2019-2026)
11.2. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By End User (2027-2033)
12. Asia-Pacific In-Vitro Fertilization (IVF) Market, By Region, 2019-2033 (USD Million)
12.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Region (2019-2026)
12.2. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Region (2027-2033)
12.3. Australia
12.4. China
12.5. India
12.6. Indonesia
12.7. Japan
12.8. Malaysia
12.9. Myanmar
12.10. New Zealand
12.11. Philippines
12.12. Singapore
12.13. South Korea
12.14. Thailand
12.15. Vietnam
12.16. Rest of Asia-Pacific
13. Company Profile
13.1. Alcon
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Bausch Health Companies Inc.
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Carl Zeiss AG
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Cooper Companies
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Johnson & Johnson
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. MaxiVision Eye Hospital
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Rayner Surgical Group Limited
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Schwind eye-tech-solutions GmbH & co.kg.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. STAAR Surgical Company
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Ziemer Group AG
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope